Mad Paws (ASX:MPA) looks like it is immune to inflation, so why are investors still deaf to its story?

Nick Sundich Nick Sundich, June 27, 2023

What’s not to like about Mad Paws (ASX:MPA)? It is one of the few ASX stocks with exposure to the pet market and is seemingly immune to inflation – at least, if today’s trading update is anything to go by.

So, why is it down over 50% since its IPO and hardly budged today?




Mad Paws releases a solid trading update

As FY23 draws to a close, Mad Paws released a trading update. It is expecting $24.5-$24.5m which would be up 146% on a reported basis and up 60% on a pro forma basis.

Whilst so many other consumer facing stocks are reporting downgrades left right and centre as consumers cut back their spending, Mad Paws is going in the opposite direction.

So why are investors seemingly tone deaf to this company? It is down over 50% since its IPO.


Mad Paws (ASX:MPA) share price chart, log scale (Source: TradingView)


Top line good, but the bottom line…not so much

Without giving specific details, Mad Paws boasted that it had seen continued improvement in EBITDA margins and was on track for EBITDA positivity in Q1 of FY24.

Investors seemingly are in the mindset of Charlie Munger.



Not a word was said about (proper) profitability.

Still, Mad Paws told shareholders there was a lot to look forward to. In particular, it boasted about plans to expand its Pet Chemist range and a new website. When (or indeed if) it will make any difference to the bottom line is anyone’s guess.


Stocks Down Under Concierge is here to help you pick winning stocks!

The team at Stocks Down Under have been in the markets since the mid-90s and we have gone through many ups and downs. We have written about every sector!

Our Concierge BUY and SELL service picks the best stocks on ASX. We won’t just tell you what to buy – we give you a buy range, price target, a stop loss level in order to maximise total returns and (of course) we tell you when to sell. And we will only recommend very high conviction stocks where substantial due diligence has been conducted.

Our performance is well ahead of the ASX200 and All Ords.

You can try out Concierge for 3 monthsfor FREE.




There’s no credit card needed – the trial expires automatically.


Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

best stocks

5 Best Stocks Under $100 To Buy Now

If you’re new to investing and don’t have a lot of money to start with, will you be missing out…

Telix Pharmaceuticals on the Nasdaq

Telix Pharmaceuticals (ASX:TLX): Is there further upside to be excited for in FY25?

What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…

like for like sales

Like for like sales: What does it mean and why do retailers use that creative term?

ASX retailers often use ‘like for like’ sales in addition to total sales. It is most common for companies that…